The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
CD 155, an onco‐immunologic molecule in human tumors
Open accessAbstract
CD 155 is the fifth member in the nectin‐like molecule family, and functions as the receptor of poliovirus; therefore, CD 155 is also referred to as necl‐5, or PVR. As an immunoglobulin‐like adhesion molecule, CD 155 is involved in cell motility, and natural killer and T cell‐mediated immunity. CD 155 is barely or weakly expressed in various normal human tissues, but frequently overexpressed in human malignant tumors. CD 155 overexpression promotes tumor cell invasion and migration, and is associated with tumor progression and poor prognosis. As the ligand for both costimulatory receptor CD 226 and coinhibitory receptor TIGIT and CD 96 on natural killer and T cells, CD 155 seems to play a dual role in oncoimmunity. However, some recent studies indicate that CD 155 overexpression may induce tumor immune escape. Taken together, CD 155 may be considered as a target for the treatment of tumors with CD 155 overexpression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
Stanietsky, N., Simic, H., Arapovic, J., Toporik, A., Levy, O., Novik, A., Levine, Z., Beiman, M., Dassa, L., Achdout, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903474106 · Cited by 3,524
Decreased expression of DNAM‐1 on NK cells from acute myeloid leukemia patients
Sanchez‐Correa, B., Gayoso, I., Bergua, J. M., Casado, J. G., Morgado, S., Solana, R., & Tarazona, R. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2011.15 · Cited by 228
Mueller, S., & Wimmer, E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304166200 · Cited by 90
Cited by
Exploring the NK cell platform for cancer immunotherapy
Myers, J. A., & Miller, J. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,276
Oncolytic virotherapy: basic principles, recent advances and future directions
Lin, D., Shen, Y., & Liang, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01407-6 · Cited by 459
Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis
Mathewson, N. D., Ashenberg, O., Tirosh, I., Gritsch, S., Perez, E. M., Marx, S., Jerby-Arnon, L., Chanoch-Myers, R., Hara, T., Richman, A. R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.022 · Cited by 408
NK Cell-Based Immune Checkpoint Inhibition
Khan, M., Arooj, S., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00167 · Cited by 356
Regulation of Src Family Kinases during Colorectal Cancer Development and Its Clinical Implications
Jin, W. (2020) · Cancers · doi:10.3390/cancers12051339 · Cited by 86
Metadata
- Authors
- Gao, J., Zheng, Q., Xin, N., Wang, W., & Zhao, C.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2017-08-18
- Volume
- 108
- Issue
- 10
- Pages
- 1934-1938
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- OpenAlex
- W2737469573
- Cited by
- 199
- References
- 3
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CD 155, an onco‐immunologic molecule in human tumors. https://app.cochat.ai/papers/10.1111/cas.13324
- The paper
- Gao, J., Zheng, Q., Xin, N., Wang, W., & Zhao, C. (2017). CD 155, an onco‐immunologic molecule in human tumors. Cancer Science. https://doi.org/10.1111/cas.13324
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.